Delayed engraftment remains a major hurdle after cord blood (CB) transplantation. It may be due, at least in part, to low fucosylation of cell surface molecules important for homing to the bone marrow microenvironment. Because fucosylation of specific cell surface ligands is required before effective interaction with selectins expressed by the bone marrow microvasculature can occur, a simple 30-minute ex vivo incubation of CB hematopoietic progenitor cells with fucosyltransferase-VI and its substrate (GDP-fucose) was performed to increase levels of fucosylation. The physiologic impact of CB hematopoietic progenitor cell hypofucosylation was investigated in vivo in NOD-SCID interleukin (IL)-2Rg null (NSG) mice. By isolating fucosylated and nonfucosylated CD34 + cells from CB, we showed that only fucosylated CD34 + cells are responsible for engraftment in NSG mice. In addition, because the proportion of CD34 + cells that are fucosylated in CB is significantly less than in bone marrow and peripheral blood, we hypothesize that these combined observations might explain, at least in part, the delayed engraftment observed after CB transplantation. Because engraftment appears to be correlated with the fucosylation of CD34 + cells, we hypothesized that increasing the proportion of CD34 + cells that are fucosylated would improve CB engraftment. Ex vivo treatment with fucosyltransferase-VI significantly increases the levels of CD34 + fucosylation and, as hypothesized, this was associated with improved engraftment. Ex vivo fucosylation did not alter the biodistribution of engrafting cells or pattern of long-term, multilineage, multi-tissue engraftment. We propose that ex vivo fucosylation will similarly improve the rate and magnitude of engraftment for CB transplant recipients in a clinical setting. Ó
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Cord blood (CB) has become an important source of hematopoietic support for cancer patients lacking human leukocyte antigenÀmatched donors. The ethnic diversity, relative ease of collection, ready availability, reduced incidence, and severity of graft-vs-host disease and tolerance of higher degrees of human leukocyte antigen disparity between donor and recipient, are positive attributes when compared with unrelated donor bone marrow (BM) [1] [2] [3] [4] or cytokinemobilized peripheral blood (PB) [5] [6] [7] . However, significantly delayed neutrophil and platelet engraftment and elevated risk of graft failure are also associated with CB transplantation when compared with BM or PB transplantation [8] [9] [10] [11] [12] [13] .
A critical part of engraftment is the recruitment of primitive hematopoietic progenitor cells (HPC) to the BM. This process is likely governed by a cascade of molecular interactions between members of the selectin, integrin, and CD44 superfamilies of adhesion molecules expressed by HPC and their various counter-receptors expressed by the microvasculature of the BM [14] [15] [16] [17] [18] [19] [20] [21] . The initial step associated with homing is the rolling of HPC on the vascular endothelium of the hematopoietic microenvironment [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , an interaction mediated, at least in part, by P-and E-selectins constitutively expressed by the BM endothelium and selectin ligands expressed by the HPC, including P-selectin glycoprotein ligand (PSGL)-1 (CD162) [25] .
The delayed engraftment and elevated risk of graft failure observed for CB recipients are due, at least in part, to low total nucleated cell [26, 27] and CD34 þ cell [28] dose transplanted. However, there is also evidence that CB CD34 þ cells possess a defect in homing to BM [29, 30] . Appropriate carbohydrate modification (fucosylation) of selectin ligands appears critical for the rolling of primitive HPC on P-and E-selectins expressed by the hematopoietic microvasculature [23, 29, 30] . CB CD34 þ cells interact poorly with selectins when compared with CD34 þ cells from PB or BM. A correlation between the level of CB CD34 þ fucosylation and binding to P-and E-selectins exists with more heavily fucosylated CD34 þ cells exhibiting a greater affinity for P-and E-selectins [29] . Consistent with this observation, we demonstrate that fucosylated rather than nonfucosylated CD34 þ cells are responsible for engraftment in the NSG mouse model [31] . These observations provide a rationale for increasing the level of CD34 þ cell surface fucosylation with the goal of improving CB engraftment. Levels of cell surface fucosylation can be increased by ex vivo treatment with a1-3 fucosyltransferase (FT)-VI [29, 30, 32] . Increased levels of fucosylation augment the level of P-and E-selectin binding of CD34 þ cells and increase the levels of rolling on P-or E-selectin in vitro [29] and BM microvasculature in vivo [30] . However, the impact of ex vivo fucosylation on hematopoietic engraftment of CB remains unclear, with different groups reporting opposing findings [29, 30] .
A correlation between the level of fucosylation of engrafting hematopoietic cells and their interaction with selectins expressed by the hematopoietic microvasculature is consistent with a potentially key role for fucosylation in recruitment to the BM. Ultimately, a better understanding of the deficiencies in homing of CB CD34 þ cells will be necessary to enable the development of more effective CB transplantation techniques. Here we used the NSG mouse model to further explore the impact of fucosylation on the rate and magnitude of CB engraftment, with the goal of improving engraftment after CB transplantation in the clinic. Fucosylation, PSGL-1 expression, and homing The human chronic myelogenous leukemia cell line K562 produces solid tumor masses in the liver, kidney, and other organs, rather than engrafting to BM [34] . Although CB CD34 þ cells express PSGL-1 [16, 35, 36] , K562 cells do not (upper panel). K562 cells expressing PSGL-1 (K562/PSGL-1) were generated by electroporation (Cell-Porator; Gibco BRL, Carlsbad, CA, USA) with pcDNA3.1 (Invitrogen) containing the full complementary DNA for human PSGL-1 and a neomycin resistance cassette. Cells were then selected at low density in medium containing G418 (1 mg/mL), stained with anti-human PSGL-1 antibody KPL-1 (BD Biosciences) and isolated by fluorescenceactivated cell sorting. To measure BM homing, K562/PSGL-1 and parental K562 lines were labeled with carboxyfluorescein succinimidyl ester (CFSE). Cells (10 6 /mL) were incubated for 10 minutes at 37 C in 10 mM CFSE (Molecular Probes Invitrogen, Eugene, OR, USA), washed, incubated in medium for 1 hour at 37 C to allow efflux of unbound stain and cells treated 6 FT-VI. The following treatment groups were generated: untreated K562, FT-VIÀtreated K562, untreated K562/PSGL-1, and FTVIÀtreated K562/PSGL-1. Cells were injected intravenously into sublethally irradiated NSG recipients at 5 Â 10 6 cells/mouse (three mice per group). Mice were euthanized approximately 16 hours after injection, femora were removed, and marrow suspensions prepared for flow cytometric assessment of the levels of CFSE-positive (human K562) cells present, relative to marrow suspensions from control (uninjected) mice. 4 0 ,6-Diamidino-2-phenylindole (0.6 mg/mL; Invitrogen) was added to identify nonviable cells and O500,000 viable events acquired (LSRII flow cytometer; Becton Dickinson) and analyzed (CELLQuest Pro software; Becton Dickinson).
Materials and methods

Hematopoietic cells
Impact of fucosylation on homing of primary CB CD34
þ cells intravenously. Group 1 received no cells and provided negative background data. Mice were euthanized approximately 18 to 20 hours after injection, femora were removed and BM cell suspensions stained with APC-conjugated anti-huCD34 and PE-Cy 7Àconjugated anti-human CD38 or isotype controls (BD Bioscience) to determine whether CFSE þ cells homing to the BM were skewed toward more primitive (CD34 þ 38
0 ,6-Diamidino-2-phenylindole was used to exclude dead cells and data acquired using an LSRII flow cytometer (Becton Dickinson). A mean of O10 6 viable events were acquired for each sample and analyzed using Diva Software (Becton Dickinson).
Colony-forming unit assays to assess impact of fucosylation on homing Primitive HPC with the capacity to engraft immunodeficient mice represent a small proportion of total CD34 þ cells. Although as many CB CD34 þ cells were infused per mouse as was practically possible in the CB CD34 þ 6 FT-VI experiment described here, and large data files were acquired during flow cytometry, concerns were raised that the rarity of human events might not provide sufficient power to accurately detect differences in BM homing as a result of treatment with FT-VI. To address this concern, a parallel experimental approach was adopted. Marrow cells were plated in triplicate 1-mL cultures in 35-mm plates in medium comprising 0.9% methyl cellulose in Iscove's modified Dulbecco's medium supplemented with 30% fetal bovine serum and 3 mM L-glutamine. Growth of human CFU was stimulated by the addition of recombinant human interleukin 3 (IL-3; 10 ng/mL), human granulocyte-macrophage colony stimulating factor (GM-CSF; 10 ng/mL), human stem cell factor (SCF; 50 ng/mL) (all from R&D Systems, Minneapolis, MN, USA) and human erythropoietin (4 U/mL) (Epoetin alfa; Amgen, Inc., Thousand Oaks, CA, USA). After 14 days of incubation at 37 C in a 5% CO 2 , fully humidified atmosphere, colonies were scored using an inverted microscope.
Impact of fucosylation on hematopoietic engraftment in NSG mice CB CD34
þ cells were divided into two fractions, treated 6 FT-VI, washed and equivalent numbers of fucosylated or untreated cells injected into groups of sublethally irradiated NSG mice (n 5 5 mice/ group). Fucosylation reactions were initially performed using 10 mM Mn 2þ , however, this dose was associated with significant hematotoxicity. A significantly less hematoxic dose of 1mM Mn 2þ was subsequently used without any reduction in enzyme activity. Further, while preliminary reactions were performed at 37C, subsequent studies revealed that reactions could be performed at room temperature without and reduction in enzyme efficacy. Human engraftment was followed by analysis of serial, retro-orbital blood samples. Blood samples were treated with Lysing Buffer (BD Biosciences) to remove red blood cells before antibody staining and flow cytometric analysis performed. At specific time points, multilineage human engraftment was assessed (human T lymphocytes: huCD3, huCD4, huCD8; human B-lymphocytes: huCD19; human myeloid cells: huCD33; human platelets: huCD41a, huCD61 and human erythrocytes: huCD235a [Glycophorin A]; all BD Biosciences). For T and B lymphocytes and myeloid cells, multilineage composition of human engraftment was investigated by gating on the huCD45 þ cell population. The proportion of human-derived erythrocytes or platelets was determined from the proportion of humanstained events (huCD235a for erythrocytes and huCD41a and/or huCD61 for platelets) in the total erythrocyte or platelet population (mouse and human) as defined by their distinct forward and side scatter. Mice were euthanized after 7 weeks and human multilineage (huCD34 þ , myeloid, and lymphoid) and multi-tissue (PB, BM, spleen, and thymus) engraftment was assessed by flow cytometry using a FACSCalibur flow cytometer (Becton Dickinson) and CELLQuest Pro software (Becton Dickinson).
Noninvasive bioluminescent imaging CB CD34 þ cells were transduced with a lentivirus vector coding for
Firefly luciferase as described previously [37] [38] [39] . Supernatant containing the lentivirus was adsorbed to a plate-bound recombinant fibronectin fragment (FN CH-296; Retronectin; Takara Shuzo, Otsu, Japan) and CB CD34 þ cells added. After lentiviral transduction, the cells were incubated at 37 C for 72 hours in medium containing 100 ng/mL each of SCF, Flt-3 ligand, and thrombopoietin (all CellGenix, Antioch, IL, USA) and granulocyte colonystimulating factor (Neupogen; Amgen, Inc. 6 cells/mL in aMEM medium (HyClone, Logan, UT, USA) containing 10% fetal bovine serum (HyClone). Cell viabilities were assessed using trypan blue dye exclusion immediately before and 1, 2, and 3 days after culture. CB CD34 þ cells were incubated in HBSS/ HSA containing FT-VI, 1 mM GDP b-fucose and 0, 1, 2, 4, 8, or 10 mM Mn 2þ for 30 minutes at room temperature. After incubation, cells were washed and levels of fucosylation assessed by flow cytometry using the HECA-452 antibody (BD Bioscience).
Statistical analysis
Data were compared using the Student's two-sample t test to test for differences between treatment groups using a two-sided significance level of 0.05.
Results
CB CD34
þ cells have lower levels of endogenous fucosylation than BM or PB CD34 þ cells Flow cytometric analysis revealed that 15% 6 3% (n 5 18, mean 6 standard error of mean) of fresh CB CD34 þ cells and 13% 6 2% (n 5 9) of thawed CB CD34 þ cells were fucosylated as defined by the binding of anti-CLA antibody HECA-452. By comparison, the fucosylation of BM and PB CD34 þ cells was significantly greater (O2-fold; p # 0.05) than that found on CB CD34
þ cells at 39% 6 12% (n 5 6) and 35% 6 7% (n 5 27), respectively (Fig. 1A) . þ cells) failed to show significant levels of human engraftment. Representative data from one experiment is shown (Fig. 1B) þ cells at 0.05% 6 0.02% and 0.25% 6 0.06%, respectively.
Ex vivo FT-VI treatment increases fucosylation of CB CD34
þ cells Optimization of the fucosylation reaction involved the assay of enzyme concentration, duration of reaction, Mn 2þ concentration, temperature, and the presence of GDP b-fucose. With a fixed number of CB mononuclear cells, fucosylation levels increased in proportion to enzyme concentration and duration of incubation until a plateau of O95% fucosylation was achieved (Fig. 1C) . Incubation at 37 C did not improve levels of fucosylation over incubation at room temperature (data not shown). Although the enzymatic reaction was absolutely dependent on the addition of the GDP b-fucose substrate, it was not absolutely dependent on the presence of Mn 2þ . The reaction conditions selected for these studies were treatment of CD34 þ cells/mL for 30 minutes at room temperature with 94 mU/mL recombinant FT-VI in a HBSS/HSA reaction mixture containing 1 mM GDP b-fucose and 1 mM Mn 2þ . These conditions reproducibly increased the proportion of fucosylated (HECA þ ) CB CD34 þ cells to O90%. Use of mean fluorescence intensity allowed a more quantitative measure of fucosylation. In a representative example (Fig. 1D) , mean fluorescence intensity of untreated CB CD34 þ cells was increased more than twofold from 436 to 990 arbitrary units when treated with FT-VI. The increased level of cell surface fucosylation after incubation remained stable for at least 2 hours at room temperature (data not shown).
Evidence for a fucosylation-dependent, PSGL-1Àmediated mechanism for BM homing Flow cytometric analysis confirmed high level expression of PSGL-1 by K562 after transfection (K562/PSGL-1) (Fig. 2A) . After FT-VIÀmediated fucosylation, both parental (upper panel) and K562/PSGL lines (lower panel) demonstrated high levels of binding of HECA-452, indicating efficient fucosylation (Fig. 2B) . Sublethally irradiated mice were then injected intravenously with equal numbers of parental K562 6 FT-VI or K562/PSGL-1 6 FT-VI and euthanized after 16 hours. Flow cytometry of BM cells revealed the number of CFSE-positive K562 cells. Analysis revealed the following: consistent with previous reports [34] , parental K562 cells did not home aggressively to the BM; FT-VI treatment of K562 cells did not improve BM homing observed with parental K562 (Fig. 2C) ; homing of K562/PSGL1 cells was not significantly different from that of K562 parental, or FT-VIÀtreated K562 cells; treatment of K562/PSGL-1 cells with FT-VI (K562/PSGL-1 þ FT-VI) markedly increased the level of fucosylation (Fig. 2B, lower panel, black fill) and significantly (p # 0.05) improved BM homing (2.8-fold) over that observed with K562 cells alone (Fig. 2C) . Collectively, these data provide evidence for a fucosylation-dependent, PSGL-1Àmediated mechanism for BM homing.
Flow cytometric analysis fails to reveal any improvement in CB CD34
þ cell recruitment to BM after FT-VI treatment Analysis of untreated cells (groups 2À4) revealed that the endogenous level of CB CD34 þ fucosylation was 12.6% 6 0.7%. These data are consistent with those reported in Figure 1A . Analysis of FT-VIÀtreated cells (groups 5À6) revealed that the level of CB CD34 þ fucosylation after treatment with FT-VI was significantly (p 5 0.00003) increased to 74.2% 6 1.5%.
Approximately 10 5 CFSE-labeled CB CD34 þ cells were injected per mouse in triplicate for each group. Flow cytometric analysis of femoral marrow was performed 18 to 20 hours after injection. BM from sublethally irradiated NSG mice receiving no cells provided a negative control (group 1) (Fig. 3A) . No significant differences were detected between the levels of homing of CD34 þ cells under any of the conditions used, irrespective of buffer composition, or treatment with FT-VI (groups 2À6). Representative flow cytometric analyses of CFSE-positive CD34 þ cells from femoral BM of mice receiving no CD34 þ cells (group 1), untreated (group 2), and FT-VIÀtreated CD34 þ cells (group 5) is shown (Fig. 3B) . Flow cytometric analysis also revealed that 89.5% 6 1.1% (n 5 15) of the CFSEpositive cells injected were CD34 þ and 5.5% 6 0.8% (n 5 15) were CD34 þ 38 lo/À . This was not changed when human cells from the NSG recipient BM were assayed.
CFC assays reveal an FT-VIÀmediated improvement in CB CD34
þ cell recruitment to BM As shown in Figure 4AÀC , FT-VIÀmediated fucosylation of transplanted CD34 þ cells resulted in a significant 4.4-fold increase (p ! 0.001) in the numbers of human CFU-GM (myeloid), an 8.1-fold increase (p 5 0.008) in the numbers of human BFU-E (erythroid) and a 6.5-fold increase (p ! 0.001) in the numbers of human CFU-GEMM (multipotent) in the BM of recipient mice 7 days after transplantation over the corresponding levels of human progenitors in mice receiving untreated CD34 cells. This trend was similarly maintained for all of these measures of HPC (CFU-GM, BFU-E, and CFU-GEMM) at 14 and 21 days after transplantation. In recipients of FTVIÀtreated CD34 þ cells, CFU-GM numbers were increased 3.8 and 2-fold (p 5 0.008 and p ! 0.001, respectively) over numbers found in marrow of recipient mice receiving untreated CD34 þ cells at 14 and 21 days. BFU-E were similarly increased by 2.2 and 1.8-fold (p ! 0.001 for both 14 and 21 days) and CFU-GEMM were similarly increased by 3.5 and 2.4-fold at 14 and 21 days (p ! 0.001 and p 5 0.001, respectively) ( Fig. 4B and C) .
Rapid and sustained engraftment after transplantation of FT-VIÀtreated CB CD34 þ cells We investigated the effects of fucosylation on the kinetics and duration of multilineage engraftment. In NSG mice receiving 4.5 Â 10 4 fucosylated CB CD34 þ cells, flow cytometry revealed a rapid increase of huCD45 þ cells in the PB approximately 3 weeks after transplantation (Fig. 5A) , more rapid than in mice receiving the same number of untreated huCD34 þ cells. Long-term human engraftment was measured by the magnitude of human engraftment in PB at 8 weeks after transplantation. In recipients of fucosylated CB CD34 þ cells, the huCD45 þ fraction was approximately 6%, as compared with approximately 2% in recipients of untreated CB CD34 þ cells (p # 0.05).
Fucosylation enhances multilineage reconstitution in the BM and spleen Eight weeks after transplantation, analysis of PB revealed that transplantation of CB CD34 þ þ FT-VI cells increased the level of huCD33 þ (myeloid) and huCD19 þ (B-cell) cell engraftment approximately threefold more than that observed in mice receiving untreated CB CD34 þ cells (Fig. 5B) . Other lineages, including red blood cells and platelets, were statistically indistinguishable between FT-VIÀtreated and untreated groups. In the spleen, transplantation of CB CD34 þ þ FT-VI cells enhanced the level of huCD33 þ (p 5 0.04) and huCD19 þ cell (p 5 0.03) engraftment after 8 weeks (Fig. 5C ), a pattern similar to that observed in PB. A comparison of the multilineage contribution to human engraftment in BM revealed no statistical difference between lineages for FT-VIÀtreated and untreated recipients (Fig. 5D) . Consistent with the absence of any difference in huCD3 þ T cells in the PB, spleen, and BM, no differences in huCD3 þ T cells or in the huCD4:huCD8 cell ratio, were seen in the thymuses of either group (data not shown).
Fucosylation does not disrupt the spatial distribution of engrafting CD34
þ CB in vivo A representative image taken 11 days after transplantation of luciferase-labeled CB CD34 þ cells revealed 2.5-fold greater levels of bioluminescence (2.5 times the mean signal intensity) in mice receiving the FT-VIÀtreated CB CD34 þ cells when compared with mice receiving untreated CB CD34 þ cells (Fig. 5E) . Ventral views suggest engraftment in the long bones of the hind limb, the sternum, and rib cage. Dorsal views suggest engraftment in the vertebral column and cranium. These data confirm that FT-VI treatment enhanced early engraftment (rate and magnitude), but did not alter the spatial distribution of transplanted cells. (10, 8, 4 , 2, 1, and 0 mM) for 30 minutes at room temperature, there was no reduction in the proportion of CD34 þ cells that became fucosylated (Fig. 6C) . These data suggest that fucosylation driven by FT-VI can occur in reduced concentrations of Mn 2þ (!10 mM) and even in the absence of Mn 2þ .
Discussion
Delayed neutrophil and platelet engraftment remains a major barrier to the successful use of CB transplantation in the clinic when compared with BM and PB sources. This might be due, at least in part, to a deficiency in the homing of CB HPC and is likely a consequence of low levels of endogenous fucosylation [29, 30] (Fig. 1A) . We show that the engraftment observed in NSG mice when transplanted with total CD34 þ cells (containing both fucosylated and unfucosylated CD34 þ cells) is the result of the fucosylated
þ population (Fig. 1B) contained therein. These data might therefore predict that engraftment would be delayed after CB transplantation when compared with the BM or PB transplantation. Such observations provide the rationale for increasing the levels of fucosylation of CB CD34 þ cells by the ex vivo use of FT-VI (Fig. 1D ) with the goal of improving engraftment. We hypothesize that increasing the levels of fucosylation of CB HPC will increase the affinity with which the cells bind to P-and E-selectins constitutively expressed by BM endothelium, thereby improving homing and subsequently improving CB HPC engraftment in the clinic. To investigate the potential role of specific cell surface molecules in the fucosylation process, we developed a model system using the NSG mouse model and human K562 cells engineered to express PSGL-1 (K562/PSGL-1) [21] . In a series of short-term homing experiments in sublethally irradiated NSG mice, the infusion of CFSE-labeled K562 6 PSGL-1 6 FT-VI cells allowed homing to femoral BM to be followed by flow cytometry. Consistent with previous observations [34] , K562 cells did not home efficiently to the BM. However, neither did K562 cells treated with FT-VI, despite being heavily fucosylated (Fig. 2B) , indicating that fucosylation alone does not confer BM homing. K562/PSGL-1 cells did not appear to home to the BM any more efficiently than parental K562 cells, indicating that the expression of PSGL-1 did not intrinsically confer improved BM homing. Only the treatment of the K562/PSGL-1 cells with FT-VI markedly improved BM homing. This provided evidence for a fucosylationdependent, PSGL-1Àmediated mechanism for BM homing (Fig. 2C) . A similar fucosylation-dependent mechanism for CB CD34
þ cells was sought in a similar short-term homing experiment.
However, when CFSE-labeled CB CD34 þ cells were treated 6 FT-VI and transplanted into recipient NSG mice, no evidence for a fucosylation-dependent improvement in CB CD34
þ cell homing was found (Fig. 3) . These data are consistent with observations reported by Hidalgo and Frenette [30] , who similarly used flow cytometry and failed to find evidence for a fucosylation-dependent improvement in CB CD34 þ cell homing. However, despite this failure to demonstrate a fucosylation-dependent improvement in the shorter-term process of homing, evidence for a fucosylation-dependent improvement in the longer-term process of engraftment was found. This included the following: an increase in the rate and magnitude of human engraftment in the PB of mice receiving CB CD34 þ treated with FT-VI over those receiving untreated CB CD34 þ cells (Fig. 5A) ; an increase in the presence of human hematopoietic progenitors (Fig. 4AÀC ) in the marrow of mice receiving CD34
þ treated with FT-VI over those receiving untreated CB CD34 þ cells; and an increase in the magnitude of bioluminescence in mice subjected to noninvasive imaging after transplantation of luciferase-labeled CD34 þ treated with FT-VI over those receiving untreated CB CD34 þ cells (Fig. 5E ). The authors suggest that the failure to demonstrate improved homing in the short-term model might, at least in part, have been a consequence of the relatively low numbers of CD34 þ cells transplanted. Despite as many CB CD34 þ cells being infused per mouse as was practically possible, the limitations associated with the acquisition of rare events, despite the acquisition of large data files, might have obscured any differences in the homing of CD34 þ cells as a result of FT-VI treatment. Although the treatment of CB HPC with FT-VI improved the rate and magnitude of engraftment (Fig. 5A) , it did not alter the spatial biodistribution pattern of the engrafting human cells (Fig. 5E ). In addition, multilineage flow cytometric analysis of PB revealed that the improved human engraftment observed was a consequence of improved myeloid and B-cell cell numbers (Fig. 5B) . Although the generation of human lineage-committed cells in the NSG mouse is likely limited by the species-specific nature of some hematopoietic growth factors [40] [41] [42] [43] , the observation that FT-VI treatment significantly improved neutrophil engraftment is encouraging and consistent with the finding of increased numbers of CFU-GM and CFU-GEMM observed in the BM of recipients of CB CD34 þ cells treated with FT-VI (Fig. 4AÀC) . In addition, the treatment of CB CD34 þ cells with FT-VI does not appear to compromise long-term engraftment and, consistent with previous reports [44] , we show that the fucosylation reaction has no absolute requirement for Mn 2þ , otherwise a potentially hematotoxic material (Fig. 6AÀC ).
Conclusions
We demonstrate that ex vivo fucosylation of CB CD34 þ cells enhances both the rate and magnitude of human engraftment in NSG mice without changing the biodistribution of the engrafting cells. These studies provide evidence that ex vivo treatment of CB CD34
þ cells with FT-VI (fucosylation) before transplantation can be an effective method by which to enhance engraftment in CB recipients. These observations provide the rationale and impetus to test the effect of ex vivo fucosylation in a clinical setting with the goal of improving engraftment after CB transplantation.
